去年年底美国获批，4月初加拿大获批，4月27日起有售。二型糖尿病人可以使用口服”促进胰岛素分泌“ （非胰岛素）药物替代注射胰岛素。可以算上是个好消息。
“诺和诺德（Novo Nordisk）公司宣布，美国FDA批准其口服索马鲁肽（oralsemaglutide，商品名Rybelsus）上市，与饮食和锻炼相结合，改善2型糖尿病患者的血糖控制。每日口服一次的索马鲁肽药片是第一款获得FDA批准的口服胰高血糖素样肽-1受体激动剂（GLP-1RA）。它的出现打破了2型糖尿病患者每天或每周需要接受GLP-1RA注射的格局，为他们控制血糖提供了侵入性更小的便捷治疗选择”
zhuanlan.zhihu.com
“MISSISSAUGA, ON, April 9, 2020 ---- Health Canada has approved RYBELSUS® (semaglutide tablets) as a treatment option to improve glycemic control in adults with type 2 diabetes mellitus, along with diet and exercise.1 RYBELSUS® is the first and only glucagon-like peptide-1 (GLP-1) analogue available in a tablet and is indicated as a monotherapy when metformin is considered inappropriate due to intolerance or contraindications. RYBELSUS® can be used in combination with other medicinal products for the treatment of type 2 diabetes in adults.
RYBELSUS® will be available in pharmacies across Canada beginning April 27, 2020.“
www.newswire.ca
”
“诺和诺德（Novo Nordisk）公司宣布，美国FDA批准其口服索马鲁肽（oralsemaglutide，商品名Rybelsus）上市，与饮食和锻炼相结合，改善2型糖尿病患者的血糖控制。每日口服一次的索马鲁肽药片是第一款获得FDA批准的口服胰高血糖素样肽-1受体激动剂（GLP-1RA）。它的出现打破了2型糖尿病患者每天或每周需要接受GLP-1RA注射的格局，为他们控制血糖提供了侵入性更小的便捷治疗选择”
你似乎来到了没有知识存在的荒原 - 知乎
知乎，中文互联网高质量的问答社区和创作者聚集的原创内容平台，于 2011 年 1 月正式上线，以「让人们更好的分享知识、经验和见解，找到自己的解答」为品牌使命。知乎凭借认真、专业、友善的社区氛围、独特的产品机制以及结构化和易获得的优质内容，聚集了中文互联网科技、商业、影视、时尚、文化等领域最具创造力的人群，已成为综合性、全品类、在诸多领域具有关键影响力的知识分享社区和创作者聚集的原创内容平台，建立起了以社区驱动的内容变现商业模式。
zhuanlan.zhihu.com
“MISSISSAUGA, ON, April 9, 2020 ---- Health Canada has approved RYBELSUS® (semaglutide tablets) as a treatment option to improve glycemic control in adults with type 2 diabetes mellitus, along with diet and exercise.1 RYBELSUS® is the first and only glucagon-like peptide-1 (GLP-1) analogue available in a tablet and is indicated as a monotherapy when metformin is considered inappropriate due to intolerance or contraindications. RYBELSUS® can be used in combination with other medicinal products for the treatment of type 2 diabetes in adults.
RYBELSUS® will be available in pharmacies across Canada beginning April 27, 2020.“
Health Canada approves RYBELSUS® (semaglutide tablets) the first and only GLP-1 analogue in a pill for the treatment of adults with type 2 diabetes
/CNW/ - Health Canada has approved RYBELSUS® (semaglutide tablets) as a treatment option to improve glycemic control in adults with type 2 diabetes mellitus,...
www.newswire.ca
”
最后编辑: 2020-05-05
